Ketamine Korner: Edition 9
Ketamine Korner is a bi-weekly newsletter exploring advances in ketamine therapy, originally started by Mind Pain Relief Institute Co-Founder Dr. Rohit Aiyer.
Each edition is republished with permission from Dr. Aiyer.
Latest Research Highlight:
Research Update: Chronic pain and depression frequently co-occur, and mounting evidence suggests they are not merely comorbid—but biologically intertwined. Central sensitization, impaired descending inhibitory pathways, and glutamatergic dysregulation are implicated in both conditions.
One of the most informative clinical signals comes from studies of ketamine in neuropathic and centralized pain conditions, where reductions in pain intensity often occur alongside improvements in mood—even when pain relief is incomplete.
A randomized, placebo-controlled trial published in Pain (Sigtermans et al., 2009) demonstrated that continuous low-dose IV ketamine significantly reduced pain in patients with CRPS type I for several weeks after treatment. Importantly, secondary analyses and subsequent observational work noted parallel improvements in affective distress, suggesting ketamine’s effects may extend beyond nociception alone.
Additional evidence comes from studies in fibromyalgia and centralized pain syndromes, where ketamine has been shown to reduce pain sensitivity and hyperalgesia—mechanisms closely linked to depressive symptoms and pain catastrophizing (Noppers et al., Arthritis Research & Therapy, 2011).
More recently, neuroimaging studies have suggested that ketamine may normalize activity in brain regions involved in both pain perception and mood regulation, including the anterior cingulate cortex and prefrontal-limbic circuits (JAMA Psychiatry, 2014).
Together, these findings support the idea that ketamine may act on shared central pathways underlying both chronic pain and depression.
A Brief History of Pain–Depression Integration in Ketamine Research:
Early Separation of Disciplines: Historically, pain and depression were treated as parallel but distinct problems—managed by different specialties with different tools.
Recognition of Shared Mechanisms: By the late 2000s, research increasingly showed that chronic pain alters central nervous system processing in ways that overlap significantly with mood disorders, including impaired neuroplasticity and heightened threat signaling.
Ketamine as a Bridge Treatment: Because ketamine modulates glutamatergic transmission and enhances synaptic plasticity, it emerged as a unique candidate capable of addressing both pain amplification and depressive symptom burden within the same patient.
Current Perspective: Today, ketamine is increasingly conceptualized as a central neuromodulator, particularly relevant for patients whose pain and depression are mutually reinforcing and resistant to conventional treatments.
Mythbuster:
Myth: Ketamine treats pain and depression independently—and improvement in one has little relevance to the other.
Reality:
Pain and depression share neural circuitry, including regions involved in salience, threat detection, and emotional regulation.
Ketamine’s central effects may reduce both pain intensity and affective suffering by targeting shared mechanisms such as central sensitization and impaired inhibitory control.
Clinical outcomes often reflect this overlap, with patients reporting reduced emotional distress even when physical pain relief is partial.
This does not mean ketamine replaces rehabilitation, psychotherapy, or multimodal pain care, but it may reduce the central burden that prevents those interventions from succeeding.
Key Takeaway:
Chronic pain and depression are deeply interconnected at the neurobiological level. Ketamine’s growing evidence base suggests it may offer a unique opportunity to address both simultaneously, particularly in patients with centralized, treatment-resistant symptoms.
Ketamine is not a cure for chronic pain or depression—but when used thoughtfully within an integrated care model, it may help quiet the shared neural drivers that keep patients stuck in cycles of pain, distress, and functional impairment.
As the science evolves, so does our understanding of ketamine’s role across both psychiatry and pain medicine. Staying informed helps us separate fact from myth and design more effective, compassionate care.
Until next time, stay curious and engaged with the possibilities ahead.